Literature DB >> 22814377

Molecular basis of β-amyloid oligomer recognition with a conformational antibody fragment.

Isabel Morgado1, Karin Wieligmann, Magdalena Bereza, Raik Rönicke, Katrin Meinhardt, Karthikeyan Annamalai, Monika Baumann, Jessica Wacker, Peter Hortschansky, Miroslav Malešević, Christoph Parthier, Christian Mawrin, Cordelia Schiene-Fischer, Klaus G Reymann, Milton T Stubbs, Jochen Balbach, Matthias Görlach, Uwe Horn, Marcus Fändrich.   

Abstract

Oligomers are intermediates of the β-amyloid (Aβ) peptide fibrillogenic pathway and are putative pathogenic culprits in Alzheimer's disease (AD). Here we report the biotechnological generation and biochemical characterization of an oligomer-specific antibody fragment, KW1. KW1 not only discriminates between oligomers and other Aβ conformations, such as fibrils or disaggregated peptide; it also differentiates between different types of Aβ oligomers, such as those formed by Aβ (1-40) and Aβ (1-42) peptide. This high selectivity of binding contrasts sharply with many other conformational antibodies that interact with a large number of structurally analogous but sequentially different antigens. X-ray crystallography, NMR spectroscopy, and peptide array measurements imply that KW1 recognizes oligomers through a hydrophobic and significantly aromatic surface motif that includes Aβ residues 18-20. KW1-positive oligomers occur in human AD brain samples and induce synaptic dysfunctions in living brain tissues. Bivalent KW1 potently neutralizes this effect and interferes with Aβ assembly. By altering a specific step of the fibrillogenic cascade, it prevents the formation of mature Aβ fibrils and induces the accumulation of nonfibrillar aggregates. Our data illuminate significant mechanistic differences in oligomeric and fibril recognition and suggest the considerable potential of KW1 in future studies to detect or inhibit specific types of Aβ conformers.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22814377      PMCID: PMC3412029          DOI: 10.1073/pnas.1206433109

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  43 in total

1.  Structure determination of micelle-like intermediates in amyloid beta -protein fibril assembly by using small angle neutron scattering.

Authors:  Winnie Yong; Aleksey Lomakin; Marina D Kirkitadze; David B Teplow; Sow-Hsin Chen; George B Benedek
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-26       Impact factor: 11.205

2.  Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo.

Authors:  Dominic M Walsh; Igor Klyubin; Julia V Fadeeva; William K Cullen; Roger Anwyl; Michael S Wolfe; Michael J Rowan; Dennis J Selkoe
Journal:  Nature       Date:  2002-04-04       Impact factor: 49.962

3.  Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis.

Authors:  Rakez Kayed; Elizabeth Head; Jennifer L Thompson; Theresa M McIntire; Saskia C Milton; Carl W Cotman; Charles G Glabe
Journal:  Science       Date:  2003-04-18       Impact factor: 47.728

Review 4.  Synaptic plasticity in animal models of early Alzheimer's disease.

Authors:  Michael J Rowan; Igor Klyubin; William K Cullen; Roger Anwyl
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2003-04-29       Impact factor: 6.237

Review 5.  Abeta toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets.

Authors:  William L Klein
Journal:  Neurochem Int       Date:  2002-11       Impact factor: 3.921

Review 6.  Probing the origins, diagnosis and treatment of amyloid diseases using antibodies.

Authors:  Mireille Dumoulin; Christopher M Dobson
Journal:  Biochimie       Date:  2004 Sep-Oct       Impact factor: 4.079

7.  Mutagenic analysis of the nucleation propensity of oxidized Alzheimer's beta-amyloid peptide.

Authors:  Tony Christopeit; Peter Hortschansky; Volker Schroeckh; Karlheinz Gührs; Giorgia Zandomeneghi; Marcus Fändrich
Journal:  Protein Sci       Date:  2005-06-29       Impact factor: 6.725

8.  A specific amyloid-beta protein assembly in the brain impairs memory.

Authors:  Sylvain Lesné; Ming Teng Koh; Linda Kotilinek; Rakez Kayed; Charles G Glabe; Austin Yang; Michela Gallagher; Karen H Ashe
Journal:  Nature       Date:  2006-03-16       Impact factor: 49.962

Review 9.  Oligomeric intermediates in amyloid formation: structure determination and mechanisms of toxicity.

Authors:  Marcus Fändrich
Journal:  J Mol Biol       Date:  2012-01-12       Impact factor: 5.469

10.  Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease.

Authors:  Stefan Barghorn; Volker Nimmrich; Andreas Striebinger; Carsten Krantz; Patrick Keller; Bodo Janson; Michael Bahr; Martin Schmidt; Robert S Bitner; John Harlan; Eve Barlow; Ulrich Ebert; Heinz Hillen
Journal:  J Neurochem       Date:  2005-08-31       Impact factor: 5.372

View more
  27 in total

1.  Design and Optimization of Anti-amyloid Domain Antibodies Specific for β-Amyloid and Islet Amyloid Polypeptide.

Authors:  Christine C Lee; Mark C Julian; Kathryn E Tiller; Fanling Meng; Sarah E DuConge; Rehana Akter; Daniel P Raleigh; Peter M Tessier
Journal:  J Biol Chem       Date:  2015-11-24       Impact factor: 5.157

2.  Protein structural and surface water rearrangement constitute major events in the earliest aggregation stages of tau.

Authors:  Anna Pavlova; Chi-Yuan Cheng; Maia Kinnebrew; John Lew; Frederick W Dahlquist; Songi Han
Journal:  Proc Natl Acad Sci U S A       Date:  2015-12-28       Impact factor: 11.205

3.  Pseudocatalytic Antiaggregation Activity of Antibodies: Immunoglobulins can Influence α-Synuclein Aggregation at Substoichiometric Concentrations.

Authors:  Leonid Breydo; Dave Morgan; Vladimir N Uversky
Journal:  Mol Neurobiol       Date:  2015-04-02       Impact factor: 5.590

4.  Structural insights into Aβ42 oligomers using site-directed spin labeling.

Authors:  Lei Gu; Cong Liu; Zhefeng Guo
Journal:  J Biol Chem       Date:  2013-05-16       Impact factor: 5.157

5.  Antiparallel triple-strand architecture for prefibrillar Aβ42 oligomers.

Authors:  Lei Gu; Cong Liu; James C Stroud; Sam Ngo; Lin Jiang; Zhefeng Guo
Journal:  J Biol Chem       Date:  2014-08-12       Impact factor: 5.157

6.  Chemically-defined camelid antibody bioconjugate for the magnetic resonance imaging of Alzheimer's disease.

Authors:  Matthias Vandesquille; Tengfei Li; Chrystelle Po; Christelle Ganneau; Pascal Lenormand; Clémence Dudeffant; Christian Czech; Fiona Grueninger; Charles Duyckaerts; Benoît Delatour; Marc Dhenain; Pierre Lafaye; Sylvie Bay
Journal:  MAbs       Date:  2017-06-28       Impact factor: 5.857

Review 7.  Antibody-Based Drugs and Approaches Against Amyloid-β Species for Alzheimer's Disease Immunotherapy.

Authors:  Jing Liu; Bin Yang; Jun Ke; Wenjia Li; Wen-Chen Suen
Journal:  Drugs Aging       Date:  2016-10       Impact factor: 3.923

8.  Chemical Fluorescent Probe for Detection of Aβ Oligomers.

Authors:  Chai Lean Teoh; Dongdong Su; Srikanta Sahu; Seong-Wook Yun; Eleanor Drummond; Frances Prelli; Sulgi Lim; Sunhee Cho; Sihyun Ham; Thomas Wisniewski; Young-Tae Chang
Journal:  J Am Chem Soc       Date:  2015-08-07       Impact factor: 15.419

Review 9.  Conformational selection in amyloid-based immunotherapy: Survey of crystal structures of antibody-amyloid complexes.

Authors:  Buyong Ma; Jun Zhao; Ruth Nussinov
Journal:  Biochim Biophys Acta       Date:  2016-06-03

10.  Amyloid β-Protein C-Terminal Fragments: Formation of Cylindrins and β-Barrels.

Authors:  Thanh D Do; Nichole E LaPointe; Rebecca Nelson; Pascal Krotee; Eric Y Hayden; Brittany Ulrich; Sarah Quan; Stuart C Feinstein; David B Teplow; David Eisenberg; Joan-Emma Shea; Michael T Bowers
Journal:  J Am Chem Soc       Date:  2016-01-06       Impact factor: 15.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.